DR5

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

Retrieved on: 
Tuesday, December 5, 2023
Workforce, DR5, Sanofi, IND, Antibody, FDA, Colorectal cancer, FOLFIRI, CD20, SLE, IGM, Clinical trial, Rheumatoid arthritis, Inflammation, Investigational New Drug, Lupus, CD38, Bevacizumab, Myopathy, Myositis, Patient, Immunoglobulin M, Vaccine

In conjunction with this strategic refocusing, the Company will be reducing its workforce by approximately 22 percent.

Key Points: 
  • In conjunction with this strategic refocusing, the Company will be reducing its workforce by approximately 22 percent.
  • As a result of these actions, IGM expects to extend its cash runway into the second quarter of 2026.
  • “IGM continues to have a tremendous opportunity to transform a variety of disease areas using an entirely new class of antibody medicines,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.
  • As a part of this strategic refocusing, the Company will halt the following clinical development activities:

IGM Biosciences Announces Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
CD38, Hepatotoxicity, Lupus, Bevacizumab, RA, CRC, Investment, Progression-free survival, IGM, CD20, FOLFIRI, DR5, Clinical trial, Immunoglobulin M, G&A, GAAP, SLE, PFS, Acute myeloid leukemia, Net, Patient, Administration, Colorectal cancer, Liver, Research and development, R, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, IND, Food, Rheumatoid arthritis, Pharmaceutical industry, Medical imaging, Sanofi

MOUNTAIN VIEW, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended June 30, 2023.

Key Points: 
  • MOUNTAIN VIEW, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended June 30, 2023.
  • Collaboration Revenue: For the second quarter of 2023, collaboration revenues were $0.4 million, compared to $0.4 million for the same period in 2022.
  • Research and Development (R&D) Expenses: For the second quarter of 2023, R&D expenses were $55.7 million, compared to $47.2 million for the same period in 2022.
  • General and Administrative (G&A) Expenses: For the second quarter of 2023, G&A expenses were $13.0 million, compared to $12.4 million for the same period in 2022.

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

Retrieved on: 
Friday, June 2, 2023
Hepatotoxicity, Bevacizumab, CRC, Progression-free survival, IGM, FOLFIRI, DR5, Immunoglobulin M, PFS, Patient, Webcast, Liver, Pharmaceutical industry

MOUNTAIN VIEW, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced an update on its clinical development program for IGM-8444, a novel multivalent death receptor 5 (DR5) agonist, in patients with metastatic colorectal cancer.

Key Points: 
  • “We continue to be very pleased with the indications of clinical activity that we are observing with IGM-8444,” said Chris Takimoto, M.D., Ph.D., F.A.C.P., Chief Medical Officer of IGM Biosciences.
  • The absence of clinically significant hepatotoxicity is particularly important, as this has been a challenge for other multivalent DR5 agonists.
  • The Company will host a conference call and live webcast to provide an update on its clinical development program for IGM-8444 at 7:00 p.m.
  • A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update

Retrieved on: 
Tuesday, May 30, 2023
Bevacizumab, IGM, DR5, Immunoglobulin M, Assistant professor, MD, Patient, Colorectal cancer, Webcast, Master of Medicine, Pharmaceutical industry

MOUNTAIN VIEW, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that it will host a conference call and live webcast to provide an update on its clinical development program for IGM-8444, a novel multivalent DR5 agonist, on Friday, June 2, 2023 at 7:00 p.m. ET.

Key Points: 
  • ET –
    MOUNTAIN VIEW, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that it will host a conference call and live webcast to provide an update on its clinical development program for IGM-8444, a novel multivalent DR5 agonist, on Friday, June 2, 2023 at 7:00 p.m.
  • The Company will be providing a clinical data update on 3 mg/kg IGM-8444 + FOLFIRI (± bevacizumab) in median third line metastatic colorectal cancer patients from a non-randomized clinical trial cohort.
  • In this presentation, the Company will not be providing a clinical data update from its recently initiated randomized study of IGM-8444 + FOLFIRI and bevacizumab in second line colorectal cancer patients.
  • A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, May 12, 2023
CD38, Lupus, Bevacizumab, AACR, Investment, IGM, FOLFIRI, DR5, Clinical trial, Immunoglobulin M, American Association for Cancer Research, G&A, NK, GAAP, Acute myeloid leukemia, Patient, Administration, Autoimmune disease, Annual general meeting, Research and development, R, Research, Safety, IND, Rheumatoid arthritis, Dietary supplement, Pharmaceutical industry, Vaccine, Sanofi

MOUNTAIN VIEW, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the first quarter ended March 31, 2023 and provided an update on recent developments.

Key Points: 
  • The Company continues to advance the clinical development of IGM-8444, the Company’s IgM agonist antibody targeting death receptor 5 (DR5).
  • In April 2023, the Company presented preclinical data on IGM-8444 at the American Association for Cancer Research (AACR) Annual Meeting.
  • In April 2023, IGM presented preclinical data evaluating IGM-2644 at the American Association for Cancer Research (AACR) Annual Meeting.
  • Collaboration Revenue: For the first quarter of 2023, collaboration revenues were $0.5 million, compared to no revenue for the same period in 2022.

IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 30, 2023
CD38, Hepatotoxicity, Lupus, Bevacizumab, Society, Cell death, B-cell lymphoma, Investment, IGM, DLBCL, FOLFIRI, Multiple myeloma, DR5, Food, Clinical trial, Immunoglobulin M, NHL, Immunotherapy, Exposition, G&A, NK, GAAP, Antibody, EDT, Trial of the century, Rheumatoid arthritis, Acute myeloid leukemia, Incidence, Investigational New Drug, TDCC, Patient, Cytokine release syndrome, Administration, Autoimmune disease, Immunoglobulin G, Webcast, Toxic leukoencephalopathy, Daratumumab, Research and development, Research, R, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Autoimmunity, Safety, Pharmaceutical industry, Vaccine, Sanofi

MOUNTAIN VIEW, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent developments.

Key Points: 
  • “Also, and perhaps most significantly, the initial clinical results from IGM-8444, our anti-death receptor 5 IgM antibody, highlight the exciting potential of IgM antibodies as agonist antibody medicines.
  • The study is designed to assess the benefit of IGM-8444 when combined with the current standard of care regimen of FOLFIRI and bevacizumab.
  • In November 2022, the Company presented preclinical results at the Society for Immunotherapy of Cancer Annual Meeting.
  • IGM will host a live conference call and webcast at 4:30 p.m. EDT today, March 30, 2023, to discuss the Company’s financial results and provide a corporate update.

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

Retrieved on: 
Monday, January 9, 2023
Immunoglobulin M, Failure, Bevacizumab, DR5, PFS, FOLFIRI, IGM, Patient, KRAS, Liver disease, Liver, Immunoglobulin G, TNF, Hepatotoxicity, Vaccine, Pharmaceutical industry

MOUNTAIN VIEW, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced an update on its clinical development program for IGM-8444, a novel multivalent DR5 agonist, and announced plans for a new randomized combination trial in patients with metastatic colorectal cancer.

Key Points: 
  • Specifically, there was no drug related clinically significant hepatotoxicity, with only grade 1 and grade 2 transient liver enzyme elevations observed.
  • Responses occurred in patients with KRAS wild type and mutated tumors and in patients with or without liver metastases.
  • “We are very pleased with the initial results observed with IGM-8444,” said Chris Takimoto, M.D., Ph.D., F.A.C.P., Chief Medical Officer of IGM Biosciences.
  • These responses, especially in patients who have previously failed chemotherapy, are very encouraging and give us confidence in proceeding to further clinical development with FOLFIRI and other combination agents.

ONK Therapeutics Boosts Drug Development Experience and Expands US Presence with the Appointment of Bruce McCreedy Ph.D. as Chief Scientific Officer

Retrieved on: 
Tuesday, December 6, 2022
Virology, CD96, DR4, GMP, NK, McCreedy, DR5, Tumor microenvironment, Research, Lymphatic system, SAN, LNP, School, Medicine, Cancer, TNF, Microbiology, CD38, Hope, Doctor of Philosophy, CISH, Drug development, WEHI, Intellia Therapeutics, Patient, JLab Audio, CSO, IND, CRISPR, Gilead Sciences, Therapy, University, Management, Pharmaceutical industry, Organon, Hematology

He has been responsible for leading research organizations through the design and execution of highly successful drug development programs including currently marketed products.

Key Points: 
  • He has been responsible for leading research organizations through the design and execution of highly successful drug development programs including currently marketed products.
  • He joins ONK Therapeutics from Myeloid Therapeutics, Inc., where as CSO his responsibilities included all IND-enabling pre-clinical studies.
  • Bruce McCreedy Ph.D., CSO of ONK Therapeutics said, “I am excited to be joining ONK Therapeutics at a pivotal time in its development as it navigates its path towards clinical trials.
  • ONK Therapeutics is headquartered in the med-tech hub of Galway, Ireland, with a wholly-owned USA subsidiary, ONK Therapeutics, Inc. based at JLabs @ San Diego.

ONK Therapeutics Presents Promising In-Vivo Data of its Optimized Affinity CD38 CAR-NK Candidate, Being Developed for the Treatment of Multiple Myeloma

Retrieved on: 
Monday, August 29, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, DR5, Cancer, CD96, NOD, NK, Tumor microenvironment, Survival, SCID, CAR, Therapy, Biotechnic & Histochemistry, Multiple myeloma, Mouse, Poster, CD38, CISH, NSG, CSO, TNF, Lymphatic system, JLab Audio, Cas9, CRISPR, DR4, Metabolism, Patient, Pharmaceutical industry, Medical imaging, Vaccine

ONKT102 is the companys most advanced program, and is being advanced towards clinical development as a potential treatment for patients with relapsed or refractory multiple myeloma (MM).

Key Points: 
  • ONKT102 is the companys most advanced program, and is being advanced towards clinical development as a potential treatment for patients with relapsed or refractory multiple myeloma (MM).
  • The anti-tumor efficacy of the optimized CD38 CAR-NK cells was then evaluated in NOD scid gamma (NSG) mice inoculated with MM.1S-LUC cells.
  • Prof. Michael ODwyer, founder and CSO at ONK Therapeutics said, These results suggest that non-virally engineered, optimized affinity CD38 CAR-NK CD38 KO cells have potent anti-tumor activity in-vitro and in-vivo in a CD38 positive tumor model.
  • ONK Therapeutics is headquartered in the med-tech hub of Galway, Ireland, with a wholly-owned US subsidiary, ONK Therapeutics, Inc. based at JLabs @ San Diego.

Ellipses Pharma and SunRock Biopharma Enter Into a Licensing Agreement for a First-in-class Bifunctional HER3:TRAIL Fusion Protein

Retrieved on: 
Wednesday, May 25, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Innova, FICC, President of the Regional Government of Galicia, Patient, Ellipses, Neoplasm, HER3, DR5, Hospital, Drug development, Monoclonal antibody, Government, DR4, Cancer, MD, CEO, Fine chemical, Pharmaceutical industry

In line with its strategy, Ellipses intends to out licence EP0017 for commercialisation if it proves safe and effective in clinical trials.

Key Points: 
  • In line with its strategy, Ellipses intends to out licence EP0017 for commercialisation if it proves safe and effective in clinical trials.
  • SunRock will continue to be involved in the development of EP0017 to ensure efficient translational activities through a service agreement with Ellipses.
  • If Ellipses out-licences EP0017, SunRock will also receive milestone payments and royalties.
  • EP0017 is a first-in-class bifunctional fusion protein with a dual mechanism of action.